Evaluating Prognostic Factors for Liver Transplantation Among United States Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis Using National Registry Data

Abstract

Introduction:

Orthotopic liver transplantation has been used as a treatment for hereditary transthyretin-mediated (hATTR) amyloidosis, a rare, progressive, and multisystem disease.

Research Question:

The objective is to evaluate survival outcomes post-liver transplantation in patients with hATTR amyloidosis in the United States and assess whether previously published prognostic factors of patient survival in hATTR amyloidosis are generalizable to the US population.

Design:

This cohort study examined patients with hATTR amyloidosis undergoing liver transplant in the United States (N = 168) between March 2002 and March 2016 using data reported to the Organ Procurement and Transplantation Network (UNOS)/United Network for Organ Sharing (OPTN).

Results:

A multivariable Cox hazards regression model showed among all factors tested, only modified body mass index (kg/m² × g/L) at the time of transplant was significantly associated with survival. Higher modified BMI was associated with lower risk of death relative to a reference population (<600) with historically poor post-transplant outcomes. Patients with modified BMI 1000 to <1200 (hazard ratio [HR] = 0.27; 95% confidence interval [CI] = 0.10-0.73), 1200 to <1400 (HR = 0.20; 95% CI = 0.06-0.75), and ≥1400 (HR = 0.15; 95% CI = 0.04-0.61) exhibited improved adjusted 5-year post-transplant survival of 74%, 80%, and 85%, respectively, versus 33% in the reference population.

Discussion:

The association between a higher modified BMI threshold at the time of transplant and improved post-transplant survival suggests that the previously published patient selection criterion for modified BMI may not be applicable to the US population.

Keywords

liver transplant recipient population characteristics heart transplant recipient other transplant recipient transplant donor anonymous

Get full access to this article

View all access options for this article.

References

Hanna

. Novel drugs targeting transthyretin amyloidosis. Curr Heart Fail Rep. 2014;11(1):50–57. doi 10.1007/s11897-013-0182-4.

Hawkins

Ando

Dispenzeri

Gonzalez-Duarte

Adams

Suhr

. Evolving landscape in the management of transthyretin amyloidosis. Ann Med. 2015;47(8):625–638. doi:10.3109/07853890.2015.1068949.

Rowczenio

Noor

Gillmore

et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat. 2014;35(9):E2403–E2412. doi:10.1002/humu.22619.

Conceicao

Gonzalez-Duarte

Obici

et al. “Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016;21(1):5–9. doi:10.1111/jns.12153.

Shin

Robinson-Papp

. Amyloid neuropathies. Mt Sinai J Med. 2012;79(6):733–748. doi:10.1002/msj.21352.

Swiecicki

Zhen

Mauermann

Kyle

Zeldenrust

Grogan

et al. Hereditary ATTR amyloidosis: a single-institution experience with 266 patients. Amyloid. 2015;22(2):123–131. doi:10.3109/13506129.1019610.

Sattianayagam

Hahn

Whelan

et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2012;33(9):1120–1127. doi:10.1093/eurheartj/her383.

Gertz

Kyle

Thibodeau

. Familial amyloidosis: a study of 52 North American-born patients examined during a 30-year period. Mayo Clin Proc. 1992;67(5):428–440.

Ando

Coelho

Berk

et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31. doi:10.1186/1750-1172-8-31.

10.

Ericzon

Wilczek

Larsson

et al.

Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative?

Transplantation. 2015;99(9):1847–1854. doi:10.1097/TP.0000000000000574.

11.

Suhr

Ericzon

Friman

. Long-term follow-up of survival of liver transplant recipients with familial amyloid polyneuropathy (Portuguese type). Liver Transpl. 2002;8(9):787–794.

12.

Adams

. Recent advances in the treatment of familial amyloid polyneuropathy. Ther Adv Neurol Disord. 2013;6(2):129–139. doi:10.1177/1756285612470192.

13.

Adams

Samuel

Goulon-Goeau

et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain. 2000;123(Pt 7):1495–1504.

14.

Liepnieks

Zhang

Benson

. Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology. 2010;75(4):324–327. doi:10.1212/WNL.0b013e3181ea15d4.

15.

Carvalho

Rocha

Lobato

. Liver transplantation in transthyretin amyloidosis: issues and challenges. Liver Transpl. 2015;21(3):282–292. doi:10.1002/lt.24058.

16.

Suhr

Ericzon

. Selection of hereditary transthyretin amyloid patients for liver transplantation: the Swedish experience. Amyloid. 2012;19(suppl 1):78–80. doi:10.3109/13506129.2012.673139.

17.

Suhr

Danielsson

Holmgren

Steen

. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med. 1994;235(5):479–485.

18.

Bittencourt

Couto

Farias

Marchiori

Bosco Massarollo

Mies

. Results of liver transplantation for familial amyloid polyneuropathy type I in Brazil. Liver Transpl. 2002;8(1):34–39.

19.

Coelho

Maurer

Suhr

. THAOS—The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29(1):63–76. doi:10.1185/03007995.2012.754348.

20.

Adams

Coelho

Obici

et al. Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study. Neurology. 2015;85(8):675–682. doi:10.1212/WNL.0000000000001870.

21.

Maurer

Hanna

Grogan

et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161–172. doi:10.1016/j.jacc.2016.03.596.

22.

Suhr

Larsson

Ericzon

Wilczek

. Survival after transplantation in patients with mutations other than Val30Met: extracts from the FAP World Transplant Registry. Transplantation. 2016;100(2):373–381. doi:10.1097/TP.0000000000001021.

23.

Banerjee

Roeker

Grogan

et al. Outcomes of patients with familial transthyretin amyloidosis after liver transplantation. Prog Transplant. 2017;27(3):246–250. doi:10.1177/1526924817715463.

24.

Adams

Suhr

Dyck

et al. Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurol. 2017;17(1):181. doi:10.1186/s12883-017-0948-5.

25.

Thuluvath

Guidinger

Fung

Johnson

Rayhill

Pelletier

. Liver transplantation in the United States, 1999-2008. Am J Transplant. 2010;10(4 Pt 2):1003–1019. do: 10.1111/j.1600-6143.2010.03037.x.

26.

Dultz

Graubard

Martin

Welker

Vermehren

Zeuzem

et al. Liver transplantation for chronic hepatitis C virus infection in the united states 2002-2014: an analysis of the UNOS/OPTN registry. PLoS One. 2017;12(10):e0186898. doi:10.1371/journal.pone.0186898.

27.

Takei

Ikeda

Ikegami

Hashikura

Miyagawa

Ando

. Ten years of experience with liver transplantation for familial amyloid polyneuropathy in Japan: outcomes of living donor liver transplantations. Intern Med. 2005;44(11):1151–1156.

28.

Sa Couto

Barros

Esteves

Aragão

. Comparison of outcome data after liver transplant: familial amyloid polyneuropathy (Portuguese type) recipients versus classical indications for liver transplant:1AP3-6. Eur J Anaesthesiol. 2010;27(47):13.

29.

Yamashita

Ando

Okamoto

et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology. 2012;78(9):637–643. doi:10.1212/WNL.0b013e318248df18.

30.

Herlenius

Wilczek

Larsson

Ericzon

. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation. 2004;77(1):64–71.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.67 MB